United Therapeutics Corp. (NASDAQ:UTHR) was downgraded by analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating in a research report issued on Tuesday, The Fly reports.

Several other equities analysts have also weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics Corp. in a research report on Friday, November 4th. Cowen and Company set a $144.00 price objective on shares of United Therapeutics Corp. and gave the company a “buy” rating in a research report on Thursday, October 27th. Ladenburg Thalmann raised shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating and increased their price objective for the company from $128.00 to $138.00 in a research report on Friday, October 28th. Zacks Investment Research lowered shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, October 20th. Finally, Argus reissued a “hold” rating on shares of United Therapeutics Corp. in a research report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. United Therapeutics Corp. presently has a consensus rating of “Hold” and an average price target of $137.17.

Analyst Recommendations for United Therapeutics Corp. (NASDAQ:UTHR)

United Therapeutics Corp. (NASDAQ:UTHR) opened at 132.74 on Tuesday. United Therapeutics Corp. has a one year low of $97.52 and a one year high of $164.04. The company has a market capitalization of $5.63 billion, a P/E ratio of 8.98 and a beta of 1.39. The company’s 50-day moving average is $122.42 and its 200 day moving average is $118.39.

United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, October 27th. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.38 by $0.98. United Therapeutics Corp. had a net margin of 44.40% and a return on equity of 41.78%. The firm had revenue of $408.20 million for the quarter, compared to analyst estimates of $400.58 million. During the same period in the prior year, the firm posted $3.55 earnings per share. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. Analysts predict that United Therapeutics Corp. will post $16.29 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “United Therapeutics Corp. (UTHR) Downgraded by Barclays PLC to Underweight” was originally posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this article on another publication, it was stolen and reposted in violation of international trademark and copyright law. The legal version of this article can be read at http://www.financial-market-news.com/united-therapeutics-corp-uthr-downgraded-by-barclays-plc-to-underweight/1208374/.

In other news, CEO Martine A. Rothblatt sold 1,232 shares of the stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $132.94, for a total value of $163,782.08. Following the completion of the transaction, the chief executive officer now owns 1,372 shares of the company’s stock, valued at $182,393.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher Patusky sold 5,000 shares of the stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $131.42, for a total transaction of $657,100.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $657,100. The disclosure for this sale can be found here. Company insiders own 7.50% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Daiwa Securities Group Inc. boosted its position in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock worth $111,000 after buying an additional 150 shares during the period. Nordea Investment Management AB boosted its position in United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock worth $128,000 after buying an additional 190 shares during the period. Piedmont Investment Advisors LLC bought a new position in United Therapeutics Corp. during the third quarter worth approximately $201,000. BancorpSouth Inc bought a new position in United Therapeutics Corp. during the third quarter worth approximately $224,000. Finally, Zweig DiMenna Associates LLC bought a new position in United Therapeutics Corp. during the third quarter worth approximately $224,000.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

The Fly

Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.